SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla doubles Remdesivir production to meet 'unprecedented' demand

13 Apr 2021 Evaluate

Cipla has doubled production of COVID-19 medication remdesivir to help meet ‘unprecedented demand’ as the country battles a massive second wave of infections. India has overtaken Brazil as the world’s second-worst coronavirus-hit country after the United States, having administered about 107 million vaccine doses among a population of 1.4 billion.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1439.65 -2.05 (-0.14%)
10-Jul-2026 14:00 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1929.00
Dr. Reddys Labs. 1244.85
Cipla 1439.65
Zydus Lifesciences 1148.95
Lupin 2495.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: